More recently Asrid et al. [10] reported a rapid decrease in the delivery of chemotherapy to the tumor in patients of non-small cell lung cancer (NSCLC) after anti-VEGF therapy, highlighting the importance of drug scheduling in combination therapy when anti-VEGF is one of the drugs. Here, VEGFA is linked to neoplasm.